The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

• Kimberly H. Harrington ,

  Contributed equally to this work with: Kimberly H. Harrington, Chelsea J. Gudgeon

  Affiliation Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Chelsea J. Gudgeon ,

  Contributed equally to this work with: Kimberly H. Harrington, Chelsea J. Gudgeon

  Affiliation Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• George S. Laszlo,

  Affiliation Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Kathryn J. Newhall,

  Affiliation Amgen, Inc., Seattle, Washington, United States of America

  ⨯
• Angus M. Sinclair,

  Affiliation Amgen, Inc., Thousand Oaks, California, United States of America

  ⨯
• Stanley R. Frankel,

  Affiliation Amgen, Inc., Rockville, Maryland, United States of America

  ⨯
• Roman Kischel,

  Affiliation Amgen Research (Munich) GmbH, Munich, Germany

  ⨯
• Guang Chen,

  Affiliation Amgen, Inc., Seattle, Washington, United States of America

  ⨯
• Roland B. Walter

  * E-mail: rwalter@fredhutch.org

  Affiliations Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington, United States of America, Department of Epidemiology, University of Washington, Seattle, Washington, United States of America

  ⨯